Compare SHOP & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOP | NVO |
|---|---|---|
| Founded | 2004 | 1923 |
| Country | Canada | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.4B | 212.7B |
| IPO Year | 2015 | N/A |
| Metric | SHOP | NVO |
|---|---|---|
| Price | $170.26 | $52.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 32 | 11 |
| Target Price | ★ $165.06 | $54.25 |
| AVG Volume (30 Days) | 6.2M | ★ 15.8M |
| Earning Date | 02-10-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 2.35% |
| EPS Growth | ★ 28.16 | 10.06 |
| EPS | 1.36 | ★ 3.67 |
| Revenue | $10,696,000,000.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $31.77 | $7.25 |
| Revenue Next Year | $23.71 | $0.24 |
| P/E Ratio | $126.04 | ★ $14.30 |
| Revenue Growth | ★ 30.25 | 16.64 |
| 52 Week Low | $69.84 | $43.08 |
| 52 Week High | $182.19 | $93.80 |
| Indicator | SHOP | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 61.66 |
| Support Level | $166.91 | $47.59 |
| Resistance Level | $172.98 | $53.63 |
| Average True Range (ATR) | 5.96 | 1.19 |
| MACD | 0.83 | 0.56 |
| Stochastic Oscillator | 84.70 | 82.85 |
Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.